期刊文献+

紫杉醇联合异环磷酰胺治疗晚期非小细胞肺癌31例 被引量:1

Clinical Study of Paclitaxel Combined with Ifosfamide for 31 Patients of Advanced Non-small Cell Lung Cancer
下载PDF
导出
摘要 目的:初步探讨紫杉醇联合异环磷酰胺治疗晚期非小细胞肺癌的疗效及毒副作用.方法:用紫杉醇联合异环磷酰胺治疗晚期非小细胞肺癌31例.紫衫醇(175 mg/m2d1)静滴3 h,异环磷酰胺(1.5 g/m2 d1~3)静滴6~8 h.21 d为1个周期,连续2~6个周期.结果:完全缓解1例,部分缓解7例,稳定17例,进展6例.总有效率25.8%.毒副作用主要有WBC减少,脱发,恶心、呕吐,肌肉酸痛.结论:紫杉醇联合异环磷酰胺治疗晚期非小细胞肺癌疗效肯定,毒性可以耐受. Objective: To evaluate the curative effect and toxic side-effects of paclitaxel combined with ifosfamide in the treatment of advanced non-small cell lung cancer. Methods: Thirty-one patients were injected with intravenous infusion of paclitaxol(175 mg/m^2 dl )for 3 hours, and ifosfamide(1.5 g/m^2 dl.3)for 6-8 hours. Each cycle was 21 days. Results: The overall effective rate was 25.8% with complete remission of one case and partial remission of 7 cases. The main toxic side-effets were leucopenia, alopenia, nausea and vomiting, muscle aching pain. Conclusion: Paclitaxel combined with ifosfamide is the effective method for advanced non-small cell lung cancer.
出处 《汕头大学医学院学报》 2005年第4期208-209,共2页 Journal of Shantou University Medical College
关键词 非小细胞肺癌 联合化疗 紫杉醇 异环磷酰胺 non-small cell lung cancer combined chemotherapy paclitaxel ifosfamide
  • 相关文献

参考文献4

二级参考文献19

  • 1Johnson SA,Harper P,Hortobagyi GN,et al.Vinorelbine:an overiew[J].Cancer Treatment Reviews,1996,22(3):127-142.
  • 2Cardenal F,Rosell R,An ton A,et al.Gemcitabine plus cisplatin versus etoposide plus cisplatin in advanced non-small cell lung cancer patients.Preliminary randomized phase Ⅱ study[J].Proc Am Soc Clin Oncol,1997,16(5):458.(abstr 1684)
  • 3Crino L,Conte P,De Marinis F,et al.A randomized trial of gemcitabine cisplatin versus mitomycin,ifosfamide and cisplatin(MIC) in advanced non-small cell lung cancer(Nsclc):A multicenter phase Ⅲ study[J].Proc Am Soc Clin Oncol,1998,17(5):455.(abstr 1750)
  • 4Jones SF,Burris HA.Vinorelbine:a new antineoplastic drug for the treatment of non-small-cell lung cancer[J].Ann Pharmacother,1996,30(5):501-506.
  • 5[2]Fossella FV, DeVore R, Kerr RN, et al. Randomized phase Ⅲ trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group. J Clin Oncol,2000,18(12)∶2354-2362.
  • 6[3]Ellis PA, Smith IE, Hardy JK, et al. Symptom relief with MVP chemotherapy in advanced non-small-cell lung cancer. Br J Cancer,1995,71(2)∶366-370.
  • 7[4]Buccheri G, Vola F, Ferrigno D. Aspects of quality of life of patients with lung cancer: a three observer evaluation in study. Int J Oncol,1993,2(2)∶537-544.
  • 8[5]Ferrigno D, Buccheri G. Second-line chemotherapy for recurrent non-small cell lung cancer: do new agents make a difference? Lung Cancer,2000,29(2)∶91-104.
  • 9[6]Shepherd FA, Dancey J, Ramlau R, et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol,2000,18(10)∶2095-2103.
  • 10[7]Akerley W 3rd. Paclitaxel in advanced non-small-cell lung cancer: an alternative high-dose weekly schedule. Chest,2000,117(4 Suppl 1)∶152S-155S.

共引文献40

同被引文献39

引证文献1

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部